Search research articles
Contact Us
Filters
Showing results (1-10 of 83) with videos related to
Page
of 9
Sort By:
Current Drug Targets
|
March 9, 2013
PPAR-γ: therapeutic prospects in Parkinson's disease
Anna R Carta
American Journal of Infection Control
|
February 1, 1982
Presumed transfer of hepatitis antibody by blood transfusion to chronic hemodialysis patients
J R Carta
Expert Opinion on Investigational Drugs
|
September 18, 2014
Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson's disease
Anna R Carta, Tanya Simuni
Journal of Integrative Neuroscience
|
September 22, 2022
BDNF Alterations in Brain Areas and the Neurocircuitry Involved in the Antidepressant Effects of Ketamine in Animal Models, Suggest the Existence of a Primary Circuit of Depression
Ezio Carboni, Anna R Carta
Neurotoxicity Research
|
August 8, 2012
Modulating microglia activity with PPAR-γ agonists: a promising therapy for Parkinson's disease?
Anna R Carta, Augusta Pisanu
Neuroscience
|
April 28, 1999
Lack of a role for the D3 receptor in clozapine induction of c-fos demonstrated in D3 dopamine receptor-deficient mice
A R Carta, C R Gerfen
Handbook of Experimental Pharmacology
|
July 30, 2009
Adenosine A2A receptors and Parkinson's disease
Micaela Morelli, Anna R Carta, Peter Jenner
Behavioural Pharmacology
|
August 31, 2006
How reliable is the behavioural evaluation of dyskinesia in animal models of Parkinson's disease?
Anna R Carta, Annalisa Pinna, Micaela Morelli
Medical Hypotheses
|
April 29, 2020
Can pioglitazone be potentially useful therapeutically in treating patients with COVID-19?
Elena Carboni, Anna R Carta, Ezio Carboni
Methods in Molecular Biology (Clifton, N.J.)
|
January 9, 2013
The MPTP/probenecid model of progressive Parkinson's disease
Anna R Carta, Ezio Carboni, Saturnino Spiga
Page
of 9
Search research articles
Search
Showing results (1-10 of 83) with videos related to
Sort By:
Page
of 9
Current Drug Targets
|
March 9, 2013
PPAR-γ: therapeutic prospects in Parkinson's disease
Anna R Carta
American Journal of Infection Control
|
February 1, 1982
Presumed transfer of hepatitis antibody by blood transfusion to chronic hemodialysis patients
J R Carta
Expert Opinion on Investigational Drugs
|
September 18, 2014
Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson's disease
Anna R Carta, Tanya Simuni
Journal of Integrative Neuroscience
|
September 22, 2022
BDNF Alterations in Brain Areas and the Neurocircuitry Involved in the Antidepressant Effects of Ketamine in Animal Models, Suggest the Existence of a Primary Circuit of Depression
Ezio Carboni, Anna R Carta
Neurotoxicity Research
|
August 8, 2012
Modulating microglia activity with PPAR-γ agonists: a promising therapy for Parkinson's disease?
Anna R Carta, Augusta Pisanu
Neuroscience
|
April 28, 1999
Lack of a role for the D3 receptor in clozapine induction of c-fos demonstrated in D3 dopamine receptor-deficient mice
A R Carta, C R Gerfen
Handbook of Experimental Pharmacology
|
July 30, 2009
Adenosine A2A receptors and Parkinson's disease
Micaela Morelli, Anna R Carta, Peter Jenner
Behavioural Pharmacology
|
August 31, 2006
How reliable is the behavioural evaluation of dyskinesia in animal models of Parkinson's disease?
Anna R Carta, Annalisa Pinna, Micaela Morelli
Medical Hypotheses
|
April 29, 2020
Can pioglitazone be potentially useful therapeutically in treating patients with COVID-19?
Elena Carboni, Anna R Carta, Ezio Carboni
Methods in Molecular Biology (Clifton, N.J.)
|
January 9, 2013
The MPTP/probenecid model of progressive Parkinson's disease
Anna R Carta, Ezio Carboni, Saturnino Spiga
Page
of 9